Amylin Pharmaceuticals Inc. (AMLN)

[surf1944]

12:59AM Amylin Pharma reports SYMLIN use helped patients with Type 2 or Type 1 Diabetes achieve more time in normal glucose range (AMLN) 27.50 : Co announces results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN injection treatment was used along with insulin. Two abstracts highlighting the analyses evaluated the proportion of readings from self-monitored seven-point glucose profiles that fell above, below or within glycemic targets based on guidelines set by the American Diabetes Association and American Association of Clinical Endocrinologists. In April of this year, the ADA and the European Association for the Study of Diabetes published a new Position Statement on the management of hyperglycemia in type 2 diabetes. The Position Statement included key clinical considerations for the use of SYMLIN, reaffirming its use in conjunction with mealtime insulin to decrease post-meal glucose excursions.